

Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China

Lan-Ying Gou^{1,2}
Yi-Long Wu¹

¹Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, ²Southern Medical University, Guangzhou, People's Republic of China

Abstract: Lung cancer is a leading cause of cancer-related mortality worldwide and in the People's Republic of China. Recently, the pathological proportions of the various forms of lung cancer have changed. A shift to a preponderance of adenocarcinoma at the expense of squamous cell carcinoma is observable. Treatment decisions have historically been based on tumor histology, and evolution of our molecular understanding of cancer has led to development of targeted therapeutic agents. It is essential to further understand mutations that drive cancer development (driver mutations) in relevant genes and their effects on cancer cell proliferation and survival. The epidemiology of lung cancer in the People's Republic of China has been extensively reviewed elsewhere. However, molecular epidemiological data from mainland China are scarce. Consequently, we herein review the prevalence of driver mutations in Chinese patients.

Keywords: lung cancer, driver mutation, prevalence, *EGFR*, *EML4-ALK*, *KRAS*, *ROS1*, *PIK3CA*, *BRAF*, *RET*, *HER2*

Introduction

As reported in the Chinese Cancer Registry Annual Report in 2012,¹ lung cancer is the leading cause of cancer-related death in the People's Republic of China. Mortality from this cancer was 45.57 per 100,000 of the national population, being 61.00 for 100,000 males and 29.77 for 100,000 females. Male mortality was 2.05-fold that of female mortality. A shift in the relative frequency of lung cancer type from squamous cell cancer to adenocarcinoma is evident both domestically and overseas in countries where numbers of male smokers remain high.² Most Chinese women do not smoke. However, in most areas, the frequency of smoking is increasing among women. Wang et al³ studied 32,845 patients with newly diagnosed lung cancer between 1998 and 2007 (Table 1). In terms of cancer subtype, the proportion of squamous cell cancers decreased annually from 30.41% (333/1,095) in 1998 to 24.16% (638/2,641) in 2007, while the proportion of adenocarcinomas increased from 42.83% (469/1,095) to 46.80% (1,236/2,641) over the same period. In women, the decline was more marked; the proportions of squamous cell cancer and adenocarcinoma were changed to 14.77% (925/6,262) and 60.83% (3,809/6,262), respectively, between 1998 and 2007. Alamoudi et al⁴ and Chang et al⁵ also found that the principal subtype of lung cancer that was histologically categorized apparently changed from squamous cell cancer to adenocarcinoma. However, the reason for this change requires further assessment.

Over the past few decades, translational research has clarified many of the molecular mechanisms for development, growth, and metastasis of lung cancer. Driver mutations occur in genes encoding signaling proteins critical in terms of cellular proliferation

Correspondence: Yi-Long Wu
Guangdong Lung Cancer Institute,
Guangdong General Hospital
and Guangdong Academy of Medical
Sciences, Guangzhou 510080,
People's Republic of China
Tel +86 20 8387 7855
Fax +86 20 8382 7712
Email syylwu@live.cn

Table 1 Distribution of pathological types of lung cancer according to gender in Beijing 1998–2007

Pathological type	Male				Female			
	Patients (n)	Ratio (%)	Crude incidence rate (per 100,000)	Adjusted rate (per 100,000)	Patient (n)	Ratio (%)	Crude incidence rate (per 100,000)	Adjusted rate (per 100,000)
AD	4,276	36.68	12.25	8.13	3,809	60.83	11.27	7.12
SCC	4,096	35.13	11.73	7.69	925	14.77	2.74	1.62
SCLC	1,630	13.98	4.67	3.08	580	9.26	1.72	1.04

Abbreviations: SCC, squamous cell cancer; AD, adenocarcinoma; SCLC, small cell lung cancer.

and survival. In lung adenocarcinomas, such mutations occur in the *EGFR*, *EML4-ALK*, *KRAS*, *ROS1*, *PIK3CA*, *BRAF*, *RET*, and *HER2* genes. Tyrosine kinase inhibitors (TKIs) targeting these genes have been developed. Such drugs include gefitinib, erlotinib, and crizotinib, which were used in the IPASS, BR.21, and Profile 1007 clinical trials, respectively.^{6–9} Many other new compounds, including the MET inhibitor tivantinib¹⁰ and the phosphatidylinositol 3-kinase inhibitor XL147,¹¹ which directly or indirectly target these driver mutations, have been developed and are undergoing clinical trials. Non-smoking-related adenocarcinoma of the lung has its peculiar epidemiologic, clinical, and biological characteristics. Many experts, including Sun et al¹² and Yano et al,¹³ have named it as a distinct entity. In recent years, many studies have shown that *EGFR*, *EML4-ALK*, *HER2*, *KRAS*, and *BRAF* mutations are mainly found in non-smoking-related adenocarcinoma.

The People's Republic of China has the highest population of any country. However, molecular epidemiological data from mainland China remain scarce. A comprehensive review of the prevalence of driver mutations is essential for development of personalized therapy targeting non-small-cell lung cancer (NSCLC). Consequently, we herein review the prevalence of driver mutations and the epidemiology of resistance mechanisms in Chinese patients with NSCLC.

Prevalence of driver mutations in lung cancers

EGFR mutations

Currently, a promising treatment strategy for advanced NSCLC features small molecules targeting epidermal growth factor receptor (EGFR) mutations.¹⁴ The prevalence of *EGFR* mutations in pulmonary adenocarcinoma among female non-smoking Asian patients was first revealed by a subgroup analysis of the Iressa Survival Evaluation in Lung Cancer trial.¹⁵ Further, several Phase III studies^{7,16,17} have compared first-line EGFR TKIs such as gefitinib and erlotinib with double platinum-based chemotherapy, used to treat NSCLC patients harboring activating *EGFR* mutations. It was found

that EGFR TKIs were associated with significantly higher response rates and afforded longer progression-free survival than did traditional chemotherapy in selected populations.

Currently, adenocarcinoma of the lung in non-smokers is recognized as a distinct disease entity because of its peculiar epidemiological, clinical, and biological characteristics; many studies have comprehensively analyzed the major known driver mutations in female non-smoking Asian patients with pulmonary adenocarcinoma. *EGFR* mutations are associated with smoking status and particular histological subtypes of disease. Wu et al¹⁸ performed a meta-analysis of up-to-date individual patient data from six medical centers of mainland China. Of 506 patients with NSCLC, the *EGFR* mutation rate in smokers was 15.1%, and lower than in non-smokers (45.5%; $P < 0.00001$). Male patients showed a lower mutation rate than female patients (23.1% versus 42.9%; $P < 0.0001$). An et al¹⁹ found that *EGFR* mutation rates varied by smoking status and the histological lung cancer subtype; these authors analyzed differences in *EGFR* mutations among patients varying in these parameters. In non-smokers with adenocarcinoma, *EGFR* was the most frequently altered gene (in 49.8%, 114/229). The mutation rates of *EGFR* in patients with adenocarcinoma and squamous cell cancer were 40.3% (140/347) and 4.4% (6/144), respectively.

In summary, *EGFR* mutations occur at high frequencies in female patients, non-smokers, those of Asian ethnicity, and patients with adenocarcinoma. Earlier Chinese studies^{19–27} recorded the frequencies of *EGFR* mutations in patients with NSCLC, adenocarcinoma, and squamous cell cancer (Table 2). Such mutations include exon 18 G719A, G719V, and G719D; exon 19 E746–A750 del, E746–S752 del, and L747–A750 (751, 753) del; exon 20 T790M and R776H; and exon 21 L858R, L858M, and L861R. As reported earlier, most *EGFR* mutations occur in exons 19 and 21. We have summarized all previous Chinese data in Figure 1D.

KRAS mutations

The *KRAS* oncogene is often mutated during carcinogenesis. Many reports have linked *KRAS* mutations to lung cancer.^{28,29}

Table 2 Frequency of EGFR and KRAS mutation and ALK rearrangements in different subgroups

Study	EGFR mutation			KRAS mutation			ALK rearrangements					
	Techniques	AD	NSCLC	AD	NSCLC	SCC	Study	Techniques	AD	NSCLC	SCC	NSCLC
Ren et al ²¹	Sequencing	70.2% (73/104)						RT-PCR	9.6% (10/104)			
Sun et al ¹⁴	Sequencing	78.8% (41/52)						RT-PCR	5.8% (3/52)			
An et al ¹⁹	Sequencing	40.3% (140/347)	28.4% (147/517)	7.1% (24/340)	5.4% (27/498)	1.5% (2/132)		RT-PCR	7.7% (10/130)		4.1% (4/93)	6.3% (15/239)
Li et al ²⁰	Sequencing	43.5% (100/230)		16.5% (38/230)				RT-PCR	3.0% (7/230)			
Xu et al ⁶⁷	ARMS	48.1% (149/310)		5.2% (16/310)				RT-PCR	7.4% (23/310)			
Li et al ⁶¹	Sequencing	44.2% (42/95)	24.5% (51/208)	4.2% (4/95)	3.37% (7/208)	1.0% (1/96)		RT-PCR	6.32% (6/95)		0 (0/96)	3.37% (7/208)
Shaozhang et al ⁶²	Sequencing	45.8% (33/72)	43.0% (44/102)	11.1% (8/72)	16.7% (17/102)			RT-PCR	6.9% (5/72)		7.1% (1/14)	8.0% (8/102)
Sun et al ⁶³	Sequencing		32.5% (26/80)		8.75% (7/80)			RACE-coupled sequencing	16.13% (10/62)		6.9% (2/29)	11.6% (12/103)
Wu et al ²⁴	Sequencing	57.3% (90/157)	40.8% (96/235)	5.03% (8/159)	3.80% (9/237)	1.56% (1/64)		Wong et al ⁴²	5.3% (11/209)		0/34	4.9% (13/266)
Xu et al ²⁶	Sequencing	47.5% (317/667)	41.0% (353/861)	9.9% (151/667)	8.0% (69/861)	1.5% (3/194)						
Gao et al ⁶⁴	ARMS	40.9% (38/93)	36.7% (44/120)	10.4% (8/77)	8.7% (9/104)			Wang et al ⁴³	10.5% (10/95)		5.6% (1/18)	9.7% (11/113)
Li et al ³⁴	HRM			4.3% (3/69)	5.8% (6/103)	3.1% (1/32)		An et al ¹⁹				5.4% (22/409)
Guan et al ³⁵	HRM				5.06% (98/1935)			Zhang et al ⁴¹	5.6% (19/341)		0/112	4.2% (20/473)
Wang et al ²²	ARMS			5.8% (16/103)								
Sun et al ²⁷	Sequencing											
Total		48.4% (675/1,395)	28.2% (570/2,021)	13.5% (264/1,955)	6.0% (274/4,585)	1.7% (12/422)			6.7% (114/1,700)		2.0% (8/396)	5.6% (108/1,913)

Abbreviations: NSCLC, non-small-cell lung cancer; AD, adenocarcinoma; SCC, squamous cell carcinoma; ARMS, amplification refractory mutation system; HRM, high resolution melting analysis; RT-PCR, reverse transcriptase polymerase chain reaction; qPCR, quantitative polymerase chain reaction; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; RACE, rapid cloning of cDNA ends.




Figure 1 (A) Frequency of driver mutation in Chinese non-small-cell lung cancer, (B) frequency of driver mutations in Chinese lung adenocarcinoma, (C) frequency of driver mutations in Chinese squamous cell carcinoma, (D) frequency of *EGFR* mutation in different subtypes, (E) frequency of *ALK* fusion in different subtypes, and (F) frequency of *KRAS* mutation in different subtypes.

Abbreviation: *EGFR*, epidermal growth factor receptor.

However, the frequency of *KRAS* mutations is lower in Eastern Asia than in the West. The *KRAS* mutation frequency is 30% or over in NSCLC patients from the USA and some other Western countries, but less than 10% in patients from Japan, Korea, Taiwan, and Hong Kong (Table 2).^{20,24,25,30–34} Other research^{19,26,35} showed that *KRAS* mutations occurred more often in males than females, in patients with adenocarcinoma compared with other forms of lung cancer, and in smokers compared with non-smokers.

Several *KRAS* mutations are known. Codon 12 mutations include G12A, G12C, G12D, G12R, G12S, G12V, G12V/C, and G12V/D. Codon 13 mutations include G13C and G13D. Guan et al³⁵ found *KRAS* mutations in codons 12 (81.32%, 74/1,935), 13 (5.49%, 5/1,935), 59 (1.10%, 1/1,935), 60 (3.30%, 3/1,935), and both 12 and 13 (5.49%, 5/1,935). The only codon 59 mutation was G59G. The codon 60 mutations were Q60H and Q60L. Mutations in both codons 12 and 13 consisted of G12D/G13D (n=3), G12C/G13C (n=1), and G12V/G13C (n=1). An et al¹⁹ enrolled 524 patients and found that 27 had *KRAS* mutations, all in codon 12, including G12C (44.4%, 12/27), G12V (18.5%, 5/27), G12D (18.5%, 5/27) and others (18.5%, 5/27).

In summary, most studies support the idea that *KRAS* mutations occur in Chinese smokers with adenocarcinoma. We analyzed studies^{19,22–27,34,35} performed in Chinese patients with lung cancer to identify the subtypes and frequencies of

KRAS mutations, and found that most occurred in codons 12, 13, 59, and 60, especially codon 12 (88%; Figure 1F). Further, *EGFR* mutations were never found in tumors with *KRAS* mutations, suggesting that these mutations are mutually exclusive.

ALK fusion genes

ALK is a receptor tyrosine kinase that is not normally expressed in the lung.³⁶ Fusions of *ALK* with an upstream gene, *EML4*, were found in NSCLC patients in 2007.³⁷ The frequency of *EML4-ALK* translocations ranges from 3% to 7% in unselected patients with NSCLC.^{38–40} Detection methods include reverse-transcriptase polymerase chain reaction (RT-PCR), fluorescence in situ hybridization, and immunohistochemistry. As with *EGFR* mutations, the frequency of *EML4-ALK* fusions is elevated in patients with adenocarcinoma, in younger adult patients, and in those who have never smoked (<100 cigarettes in a lifetime) or who are light smokers (≤ 15 pack-years). *EML4-ALK* translocations are generally found in tumors wild-type for *EGFR* and *KRAS*.³⁸ The *EML4-ALK* translocation occurs in a low proportion of lung cancers, ie, in 4%–11.6% of unselected Asian patients with early stage NSCLC.^{23,41–43} However, only small numbers of *EML4-ALK*-positive patients have been studied, because patient enrolment in most cited studies was non-selective. Thus, the relationship between

gene fusion and clinical and pathological profiles requires further study.

A careful review of the literature in the Chinese language revealed that ALK fusion proteins are frequently present in patients with lung cancer (Table 2). This table lists the frequencies of *ALK* fusions in patients with NSCLC, adenocarcinoma, and squamous cell cancer, respectively. In summary, the results show that risk factors for development of the *EML4-ALK* fusion are female gender, adenocarcinoma, non-smoking status, and relative youth. Patients with *EML4-ALK* fusions are always wild-type for *EGFR* and *KRAS*.

EML4-ALK fusions are caused by various small inversions within the short arm of chromosome 2.^{38–40} At least nine variants have been identified.³⁸ Exons 20–29 of *ALK* may be fused to *EML4* exon 13 (variant 1, V1), exon 20 (V2), exon 6 (V3a), exon 6 with an 11 amino acid insertion (V3b), exon 14 with an additional 11 nucleotide insertion of unknown origin at nucleotide 50 of exon 20 of *ALK* (V4), exon 2 (V5), exon 13 (V6), exon 14 with the fusion beginning at nucleotide 13 of exon 20 of *ALK* (V7), exon 15 (also termed “V4” [V8]), and exon 18 (also termed “V5” [V9]). The details can be found in a review by Horn and Pao.³⁸ For example, Wong et al⁴² used RT-PCR to show that the frequencies of the fusion variants 1, 2, 3, and 9 were 2/13, 2/13, 8/13, and 1/13, respectively, in Chinese patients with lung cancer. Zhang et al²³ found that the frequencies of fusion variants 1, 2, 3, 5, and 9 were 4/12, 1/12, 3/12, 1/12, and 3/12, respectively. Sun et al⁴⁴ found that variants 1, 2, and 3 were each present alone in individual Chinese patients with NSCLC using RT-PCR. Li et al²⁰ found that the frequencies of *EML4-ALK* variants 1, 2, 3, and 4 were 2/7, 1/7, 3/7, and 1/7, in Chinese patients with lung adenocarcinoma using RT-PCR. Similarly, Li et al⁶¹ found that the frequencies of fusion variants 1, 2, 3, 5, and 9 were 14/22, 3/22, 3/22, 1/22, and 1/22, respectively. No Chinese patient has been found to be positive for variant 6, 7, or 8 (Figure 1E).

ROS1 mutation

ROS1 rearrangements were initially identified in a human glioblastoma cell line.⁴⁶ Such rearrangements have been identified in approximately 1%–2% of NSCLC patients using different genotyping techniques (Table 3).^{47,48} Several recent studies used whole-transcriptome and whole-genome sequencing to detect *ROS1* rearrangements, and several novel fusion partners were identified.^{47,48} Such methods are not yet readily applicable in the clinic. Therefore, *ROS1* screening strategies have been largely informed by experience with *ALK*

testing, for which the three most commonly used methods of detection are fluorescence in situ hybridization, RT-PCR, and immunohistochemistry. *ROS1* fusions appear to be more common in patients with adenocarcinoma. Cai et al⁴⁸ found that the ratios of females to males and never-smokers to smokers in a *ROS1* fusion-positive group were 5:3. No significant differences in age ($P=0.866$), gender ($P=0.479$), smoking history ($P=1.0$), histological tumor type ($P=0.148$), or pathological stage ($P=0.475$) were evident between *ROS1* fusion-positive and fusion-negative patients.

General spectra of mutations in *PIK3CA*, *BRAF*, *RET*, and *HER2*

Recently, many studies have analyzed the spectra of well known driver mutations in non-smokers with adenocarcinoma of the lung. Table 3 shows the oncogenic driver mutations in the *ROS1*, *BRAF*, *PIK3CA*, *RET*, and *HER2* genes of such highly selected Chinese patients. Targeted therapies are developing rapidly, and molecular data in conjunction with clinical and pathological features suggest that prospective genotyping of lung adenocarcinomas in smokers, in terms of changes in the genes listed above, may facilitate targeted therapy in almost all cases.

As with *EGFR*, the *HER2* protein is a member of the *HER* family of receptor tyrosine kinases. The protein forms homodimers or heterodimers with other members of the same family. *HER2* is overexpressed in about 20% of patients with NSCLC, but gene amplification occurs in only 2%.^{49,50} Early clinical trials with trastuzumab, a humanized monoclonal antibody against *HER2* (which is effective to treat breast cancers in which *HER2* is amplified), exerted only slight effects in unselected patients with NSCLC.⁵¹

Xu et al⁶⁷ and others^{20,21,26} have shown that the frequency of the *PIK3CA* mutation in NSCLC patients is 2%–4%, and the mutation occurs less often in those with adenocarcinomas compared with other forms of lung cancer.

We have summarized the data from the Chinese studies, and describe the general spectrum of mutations in *EGFR*, *ALK*, *KRAS*, *PIK3CA*, *BRAF*, *RET*, and *HER2* in patients with NSCLC, adenocarcinoma, and squamous cell cancer, respectively (Figure 1A–C).

Mechanism of development of drug resistance in lung cancers

Most advanced NSCLCs with activating *EGFR* mutations initially respond to the TKIs gefitinib or erlotinib. However, after 6–12 months, most tumors acquire resistance to these agents. Elucidation of the mechanism underlying this

Table 3 Frequency of new driver mutations in non-small-cell lung cancers

Study	Techniques	Prevalence									
		ROSI		PIK3CA		BRAF		RET		HER2	
		AD	NSCLC	AD	NSCLC	AD	NSCLC	AD	NSCLC	AD	NSCLC
Xu et al ²⁶	Sequencing			2.7% (18/667)	7.2% (14/194)	3.7% (32/861)	0.7% (6/861)				
An et al ¹⁹	HRM			4.2% (13/307)	5.8% (7/121)	4.4% (20/452)	1.5% (7/452)	2.3% (7/307)	0%		
Ren et al ²¹	Sequencing			1.9% (2/104)		1.9% (2/104)					
Sun et al ⁴⁴	Sequencing			7.6% (4/52)		0					0% (0/104)
Li et al ²⁰	Sequencing			3.5% (8/230)		3.0% (7/230)					3.8% (2/52)
Zheng et al ⁶⁶	Sequencing					2.2% (9/409)					0% (0/230)
Xu et al ⁶⁷	Sequencing							0%	1.6% (5/310)		1.5% (6/409)
Cai et al ⁴⁸	RT-PCR	3.0% (7/231)	0 (0/19)	2.0% (8/392)							
Rimkunas et al ⁴⁷	FISH, IHC	3.3% (8/246)	0 (0/226)	1.6% (9/556)							
Total		3.14% (15/477)	0 (26/1,357)	3.3% (45/1,360)	6.7% (21/315)	4.0% (52/1,313)	1.0% (13/1,313)	1.6% (16/1,003)	1.6% (5/310)	1.5% (6/409)	0.5% (2/386)

Abbreviations: NSCLC, non-small-cell lung cancer; AD, adenocarcinoma; SCC, squamous cell carcinoma; HRM, high resolution melting analysis; RT-PCR, reverse transcriptase polymerase chain reaction; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.

Table 4 Prevalence of *T790M* mutation and *c-MET* amplification in Chinese patients with TKI-resistant NSCLC

Study	Year	Technique	<i>T790M</i> mutation		<i>c-MET</i> amplification		<i>c-MET</i> coexistent <i>T790M</i>
			TKI-naïve	TKI acquired-resistant	TKI-naïve	TKI acquired-resistant	TKI acquired-resistant
Chen et al ⁶⁵	2009	HRM	0% (0/53)	48.3% (14/29)	3.8% (2/53)	10.3% (3/29)	6.9% (2/29)
Chen et al ⁶⁶	2011	FISH			10.58% (22/208)		
Wu et al ⁵⁷	2011	RT-PCR	0.5% (6/1,261)				
He et al ⁵⁸	2013	RT-PCR		36.4% (24/33)			
		Sequencing		6.1% (2/33)			
Su et al ⁵⁹	2012	MALDI-TOF MS	25.2% (27/107)	83.3% (10/12)			
		Sequencing	2.8% (3/107)	33.3% (4/12)			
Ren et al ²¹	2012	Sequencing	7.7% (8/104)				
Total			2.8% (44/1,579)	45.4% (54/119)	9.2% (24/261)	10.3% (3/29)	6.9% (2/29)

Abbreviations: MALDI-TOF MS, matrix-assisted laser desorption ionization-time of flight mass spectrometry; NSCLC, non-small-cell lung cancer; HRM, high resolution melting analysis; RT-PCR, reverse transcriptase polymerase chain reaction; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; TKI, tyrosine kinase inhibitor.

process is important. *T790M* mutation, *MET* amplification, overexpression of hepatocyte growth factor, and activation of the insulin-like growth factor 1 receptor (IGF1R) and other factors have been reported to be associated with acquired resistance to EGFR TKIs.⁵² Most previous clinical reports indicated that acquisition of the *T790M* mutation explained approximately 50% of acquired TKI resistance in both Caucasian and Asian populations.^{53–55} Many of these studies were retrospective and enrolled small numbers of heterogeneous patients. In addition, whether the *T790M* mutation is present before treatment, the mechanism of mutation, and the optimal detection method remain controversial. Other secondary resistance mutations seem to be rare. Generally, *MET* amplification accounts for about 20% of TKI resistance; the molecular mechanism differs from that of *T790M*. In some patients, both mutations are present.

Studies of acquired resistance to EGFR TKIs in Chinese patients with lung cancer seem to be rare. We have extensively reviewed the literature on acquired resistance to TKIs in such patients and have summarized the data (Table 4).^{21,56–59} This table contains information on *T790M* mutations developing in 44 of 1,579 (2.8%) TKI-naïve patients studied in six clinical reports. However, 45.4% (54/119) were positive after failure of TKI therapy.

The increasing amount of preclinical data on *EGFR*-mutated NSCLCs that have acquired resistance to TKIs has enhanced interest in the development of novel drugs inhibiting the effects of *T790M*, *MET*, or *IGF-1R* mutations, to be used in combination with EGFR TKIs. A pan-HER TKI, PF00299804, to which resistance does not develop, has been tested in xenograft models and shows promise for use in humans to overcome *T790M*-mediated TKI resistance.⁶⁰ Ongoing clinical research on *EGFR*-mutated NSCLCs will

improve the survival of patients with somatic mutations such as *T790M*, *MET*, or *IGF-1R*.

Conclusion

Currently, non-smoker lung adenocarcinoma is the principal subtype of lung cancer, and is recognized as a distinct entity because of its peculiar biological characteristics. The frequency of *EGFR* mutations ranges from 28.0% in unselected Chinese patients with NSCLC to 48.5% in those with lung adenocarcinoma. The *KRAS* mutation frequency is lower in the People's Republic of China than in Western countries. The frequency of the *EML4-ALK* fusion is 6.4% and this mutation is often found in females, patients with adenocarcinoma, non-smokers, and younger patients. *ROS1* fusions appear to be more common in patients with adenocarcinoma. These observations have changed the treatment strategies for lung cancer. Genetic testing prior to treatment is now considered essential, to allow the best treatment option to be selected. First, *EGFR* mutation status should be tested; almost 70% of adenocarcinoma tumors have such a mutation. If the result is negative, further molecular testing is required. Treatment options include EGFR TKIs such as gefitinib or erlotinib or irreversible TKIs such as afatinib (if the *T790M* mutation is detected). If the tumor is wild-type in terms of *EGFR*, *ALK* translocations, found in about 30% of EGFR-negative tumors, should be sought. If a translocation is present, treatment would include an ALK inhibitor. If the tumor is negative for an *ALK* translocation, more rare mutations (in *KRAS*, *ROS1*, *PIK3CA*, *BRAF*, *RET*, or *HER2*) should be sought. Also, new driver mutations remain to be discovered.

Disclosure

The authors report no conflicts of interest in this work.

References

- He J, Chen WQ. The Chinese Cancer Registry Annual Report 2012[R]. 2012:65–72.
- Harkness EF, Brewster DH, Kerr KM, Fergusson RJ, MacFarlane GJ. Changing trends in incidence of lung cancer by histologic type in Scotland. *Int J Cancer*. 2002;102(2):179–183.
- Wang N, Chen WQ, Zhu WX, Xing XM, Lu AP, Yang L. [Incidence trends and pathological characteristics of lung cancer in urban Beijing during period of 1998–2007]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2011;45(3):249–254.
- Alamoudi OS. Lung cancer at a University Hospital in Saudi Arabia: A four-year prospective study of clinical, pathological, radiological, bronchoscopic, and biochemical parameters. *Ann Thorac Med*. 2010;5(1):30–36.
- Chang S, Dai M, Ren JS, Chen YH, Guo LW. [Estimates and prediction on incidence, mortality and prevalence of lung cancer in China in 2008]. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2012;33(4):391–394.
- Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. *Clin Lung Cancer*. 2006;7(6):389–394.
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009;361(10):947–957.
- Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*. 2013;368(25):2385–2394.
- Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase I study. *Lancet Oncol*. 2012;13(10):1011–1019.
- Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. *J Clin Oncol*. 2011;29(24):3307–3315.
- Shapiro GI, Rodon J, Bedell C, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. *Clin Cancer Res*. 2014;20(1):233–245.
- Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers – a different disease. *Nat Rev Cancer*. 2007;7(10):778–790.
- Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y. Non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology and clinical features. *Int J Clin Oncol*. 2011;16(4):287–293.
- Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol*. 2011;12(2):175–180.
- Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet*. 2005;366(9496):1527–1537.
- Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med*. 2010;362(25):2380–2388.
- Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*. 2011;12(8):735–742.
- Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. *J Thorac Oncol*. 2007;2(5):430–439.
- An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. *PLoS One*. 2012;7(6):e40109.
- Li H, Pan Y, Li Y, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. *Lung Cancer*. 2013;79(1):8–13.
- Ren S, Kuang P, Zheng L, et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. *Cell Biochem Biophys*. 2012;64(2):155–160.
- Wang Z, Wu YL, Zhang GC, Zhou Q, Xu CR, Guo AL. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients. *Onkologie*. 2008;31(4):174–178.
- Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. *Mol Cancer*. 2010;9:188.
- Wu CC, Hsu HY, Liu HP, et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. *Cancer*. 2008;113(11):3199–3208.
- Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. *Clin Cancer Res*. 2006;12(5):1647–1653.
- Xu J, He J, Yang H, et al. Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. *Cancer Biomark*. 2011;10(2):63–69.
- Sun LN, Luan HL, Zang FL, et al. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer]. *Zhonghua Zhong Liu Za Zhi*. 2010;32(9):667–670.
- Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. *Proc Natl Acad Sci U S A*. 1982;79(11):3637–3640.
- To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. *Nat Genet*. 2008;40(10):1240–1244.
- Keohavong P, DeMichele MA, Melacrinis AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. *Clin Cancer Res*. 1996;2(2):411–418.
- Rosell R, Monzo M, Pifarre A, et al. Molecular staging of non-small cell lung cancer according to K-ras genotypes. *Clin Cancer Res*. 1996;2(6):1083–1086.
- Sakuma Y, Matsukuma S, Yoshihara M, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. *Am J Clin Pathol*. 2007;128(1):100–108.
- Bae NC, Chae MH, Lee MH, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. *Cancer Genet Cytogenet*. 2007;173(2):107–113.
- Li M, Liu L, Liu Z, et al. The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. *Oncol Rep*. 2009;22(5):1013–1020.
- Guan JL, Zhong WZ, An SJ, et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. *Ann Surg Oncol*. 2013;20(4):1381–1388.
- Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). *Oncogene*. 1997;14(18):2175–2188.
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*. 2007;448(7153):561–566.
- Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. *J Clin Oncol*. 2009;27(26):4232–4235.
- Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res*. 2008;14(13):4275–4283.

40. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. *Cancer Res.* 2008;68(13):4971–4976.
41. Zhang YG, Jin ML, Li L, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT-PCR on paraffin-embedded tissues. *PLoS One.* 2013;8(5):e64821.
42. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer.* 2009;115(8): 1723–1733.
43. Wang Z, Zhang X, Bai H, et al. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. *Oncology.* 2012;83(5):248–256.
44. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from east asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. *Journal of Clinical Oncology.* 2010;28(30): 4616–4620.
45. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. *Proc Natl Acad Sci U S A.* 2009;106(38):16281–16286.
46. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. *Proc Natl Acad Sci U S A.* 1987;84(24):9270–9274.
47. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. *Clin Cancer Res.* 2012;18(16):4449–4457.
48. Cai W, Li X, Su C, et al. ROS1 fusions in Chinese patients with non-small-cell lung cancer. *Ann Oncol.* 2013;24(7):1822–1827.
49. Heinmoller P, Gross C, Beyser K, et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of hereceptin. *Clin Cancer Res.* 2003;9(14):5238–5243.
50. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. *Nature.* 2004;431(7008): 525–526.
51. Hirsch FR, Langer CJ. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. *Semin Oncol.* 2004;31(1 Suppl 1): 75–82.
52. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med.* 2005;2(3):e73.
53. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res.* 2006;12(21):6494–6501.
54. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci U S A.* 2007;104(52):20932–20937.
55. Jiang SX, Yamashita K, Yamamoto M, et al. EGFR genetic heterogeneity of non-small cell lung cancers contributing to acquired gefitinib resistance. *Int J Cancer.* 2008;123(11):2480–2486.
56. Chen YT, Chang JW, Liu HP, et al. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment. *J Thorac Oncol.* 2011;6(12): 2027–2035.
57. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. *Clin Cancer Res.* 2011;17(11):3812–3821.
58. He C, Zheng L, Xu Y, Liu M, Li Y, Xu J. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer. *Clin Chim Acta.* 2013;425: 119–124.
59. Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. *J Clin Oncol.* 2012;30(4):433–440.
60. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. *Lung Cancer.* 2010; 69(1):1–12.
61. Li Y, Yang T, Wei S, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. *PLoS One.* 2013;8(1):e52093.
62. Zhang SZ, Li XM, Zhang AP, Sun XQ, Yang QT. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. *Genes Chromosomes Cancer.* 2012;51(10):925–932.
63. Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. *J Exp Clin Cancer Res.* 2011;30:30.
64. Gao J, Chen JQ, Zhang L, Liang ZY. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system]. *Zhonghua Bing Li Xue Za Zhi.* 2012;41(10):652–656.
65. Chen HJ, Mok TS, Chen ZH, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. *Pathol Oncol Res.* 2009;15(4): 651–658.
66. Zheng LM, David BW, Li R, et al. Screening of NSCLC samples from Chinese lung cancer patients for activating rearrangements of the ALK, RET, and ROS1 genes[abstract]. *J Clin Oncol.* 2013;Suppl 31: e22066.
67. Xu R, Ma J, Xie LQ, et al. Frequency of oncogenic alterations in five driver genes in Chinese female lung adenocarcinoma[abstract]. *J Clin Oncol.* 2013;Suppl 31:1588.

Lung Cancer: Targets and Therapy

Publish your work in this journal

Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening; Cellular research and biomarkers; Identification of biotargets and agents with novel

Submit your manuscript here: <http://www.dovepress.com/lung-cancer-targets--therapy-journal>

mechanisms of action; Optimal clinical use of existing anticancer agents, including combination therapies; Radiation and surgery; Palliative care; Patient adherence, quality of life, satisfaction; Health economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.